Introduction
============

Traumatic brain injury (TBI) refers to an intracranial injury when external forces act on the brain and bring about severe neurobehavioral impairment ([@B23]). In recent years, the incidence, mortality and disability of TBI have been on the rise ([@B7]; [@B24]). TBI has become a major cause of death and disability worldwide, especially in children and young people ([@B2]; [@B13]). The degree of brain damage in TBI is divided into mild, moderate and severe categories ([@B35]). According to the severity, patients will present different physical, cognitive, social, emotional, and behavioral symptoms ([@B18]; [@B42]) and have outcomes from full recovery to permanent disability or death ([@B11]; [@B9]; [@B6]; [@B23]; [@B25]). The current treatment measures are nothing more than drug treatment, emergency surgery or surgery after a few years ([@B23]; [@B17]). With the development of medicine, although the current treatment measures have been greatly improved, they are not satisfactory. Consequently, further providing the molecular basis of TBI for clinical treatment has become inevitable.

Traumatic brain injury includes primary and secondary brain damage. Primary brain injury occurs during the initial period of injury due to displacement of the physical structure of the brain ([@B36]). Secondary brain injury, which may be due to primary injury or independent of its cause ([@B29]), occurs gradually and involves a series of cellular processes including damage to blood--brain barrier, release of inflammatory factors, free radical overload, excessive release of neurotransmitter glutamate (excitotoxicity), influx of calcium and sodium ions, and mitochondrial dysfunction ([@B46]; [@B28]). Nowadays, some molecules have been found to participate in the development of secondary brain injury. The gene expression profile in the rat cerebral cortex with the secondary injury of TBI was analyzed by bioinformatics analysis and the expression change of the genes was found after 48 h of TBI, whose molecular functions were steroid biosynthesis, cell cycle, metal ion transport, inflammation and the apoptosis function ([@B27]). In addition, by using microarrays and bioinformatics analysis, [@B30] confirmed 3 months after TBI miR-139-5p was downregulated and the NOTCH1 interactome was upregulated. Then, by genome-wide approach, [@B19] found that after TBI, sorting protein-related receptor with A-type repeats (SORLA) may be involved in the post-traumatic cascade linking TBI to Alzheimer's disease. Moreover, the complement factor 9 (C9), complement factor B (CFB) and aldolase c (ALDOC) in the serum of rat TBI models rose in the early stage of injury, while hypoxia inducing factor (HIF) 1α, amyloid precursor protein (APP) and Williams-Beuren syndrome chromosome region 17 (WBSCR17) increased at the late stage of injury ([@B39]). Furthermore, what proteins have changed in the serum of human with TBI? [@B4] enrolled 34 TBI subjects and 69 healthy volunteers and found an increase in glial fibrillary acidic protein (GFAP), microtubule-associated protein tau and amyloid β peptide (Aβ42) at days 0, 30, and 90 after TBI. In summary, there have been great changes in the serum proteins after TBI, but there are still few studies in this field, especially regarding the changes in human serum protein.

As the secondary injury gradually occurs and is more prominent to the body, the patient's condition may gradually deteriorate ([@B37]; [@B33]). Of the various factors, the role of inflammatory factors cannot be ignored. Previous study has reported that the gene expression in the ipsilateral hippocampus of mice with mild TBI was changed, which mapped to many ontologies and molecular pathways related to inflammation and neurological physiology/pathology, including neurodegenerative disease ([@B41]). Simultaneously, [@B26] found that CSF concentrations of inflammatory biomarkers (IL-1β, IL-6, TNF-α, IFN-γ, IL-12p70, IL-10, and IL-8) had a significant association with 6-month neurological outcome, with the favorable outcome group having lower concentrations of these biomarkers on average, in comparison to the poor neurological outcome group after severe TBI.

Growth factor is a protein, or a steroid hormone, capable of stimulating cellular growth, proliferation, and differentiation ([@B14]). At present, the role of growth factors in TBI have also been revealed. The expression of BDNF and its receptors at the acute phase following penetrating TBI of rat has been reported firstly to be altered ([@B34]). Additionally, in the blast-induced traumatic brain injury of swine, vascular endothelial growth factor (VEGF) was discovered to increase ([@B1]). Moreover, the mRNA expression of components and targets of the TGF-β, BMP, and activin signaling pathways in the subventricular zone (SVZ) and the hippocampal dentate gyrus (DG) was significantly altered after cortical injury in mice, which then induced expression of Runt-related transcription factor-1 (Runx1) that can interact with intracellular TGF-β Smad signaling pathways and promotes microglial cell activation and proliferation and neural stem cell (NSC) proliferation after TBI ([@B22]).

Although some molecules have been found to be involved in repair and deterioration of the injury, a series of cellular processes are involved after TBI, especially in the development of secondary brain injury. Therefore, these processes cannot be the result of the action of one or more molecules. Accordingly, it is necessary to continue to explore the key players after TBI injury. In this study, serum protein microarray technology and bioinformatics analysis were used to investigate what molecules in the serum of TBI patients make a difference to these changes, and what functions and pathways these molecules are mainly enriched in. In particular, the expression of growth factors and inflammatory factors in serum of TBI patients was confirmed.

Materials and Methods {#s1}
=====================

Ethics Statement and Grouping
-----------------------------

Human serum samples used in this study were provided by The First Hospital of Kunming. The patients did not receive special treatment including radiotherapy and chemotherapy. The age of the patients ranged from 18 to 81 years old (mean 46.4 years old). These 23 serum samples were collected third day after TBI and served as TBI-third group. Moreover, the sera from 22 healthy volunteers without cerebral injury and other organic diseases were selected for the control group. Patients' data was extracted by two independent reviewers, and the study type of the dataset was protein expression profile studies. Any discrepancies between reviewers were resolved by consensus or a third reviewer. This study was carried out in accordance with the recommendations of the Declaration of Helsinki, the Ethical Committee of The First Hospital of Kunming (reference number 2014-2). The protocol was approved by the Ethical Committee of The First Hospital of Kunming. All subjects gave written informed consent in accordance with the Declaration of Helsinki.

Collection of Human Serum Samples
---------------------------------

Grouping information and all the patients' information is shown in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, respectively. The whole blood of the patients was collected with coagulant tubes. After blood collection, the coagulant tubes (SANLI, Jiangsu, China) were gently reversed, and the blood was mixed four to five times and then stood upright at room temperature until the blood was completely solidified (usually about 1 h). Within 2 h after blood collection, all the serum samples were retrieved and transferred to the laboratory of the Institute of Neuroscience, Kunming Medical University. After the filtering process according to the standards, the coagulant tubes of 23 human serum samples on the TBI-third group were centrifugated with 1,000 × *g* for 10 min, and the serum was isolated. The collected serum was transferred to 1.5 ml microtubes (Axygen, United States) and divided into 200--300 μl/tube. All samples were immediately frozen in liquid nitrogen, and then stored at -80°C. Moreover, the serum obtained from control group underwent the same procedures. Finally, the samples were filled in a vessel with dry ice and transported to Shanghai Kangcheng Biological Engineering Co., Ltd. for further study.

###### 

Patients' grouping and test in both groups.

  Group             Protein microarray   ELISA/blood biochemical examination
  ----------------- -------------------- -------------------------------------
  Control group     3                    19
  TBI-third group   3                    20
                                         

###### 

Baseline clinic data of patients.

  Items               Sub items/unit               Control group       TBI-third group
  ------------------- ---------------------------- ------------------- ----------------------
  Gender              Male                         53%                 83%
                      Female                       47%                 17%
  Age                 Years old                    44.4 ± 20.56        46.4 ± 16.24
  Hematoma            Intracerebral                0                   45%
                      Epidural                     0                   30%
                      Subdural                     0                   10%
                      No                           100%                15%
  Injured part        Forehead                     0                   70%
                      Partes temporalis            0                   45%
                      Facies parietalis            0                   35%
                      Occiput                      0                   15%
  Treatment           Surgery                      *NO*                30%
                      Expectant treatment          *NO*                70%
  GCS                 Scores                       15 ± 0              13.25 ± 0.39
                                                                       
  **Other Indexes**   **Normal reference range**   **Mean ±** **SD**   **Mean ± SD**
                                                                       
  HGB                 110--160 g/L                 \-                  126.73 ± 16.21
  WBC                 (4--10) × 10^9^/L            \-                  9.06 ± 4.48
  NEUT                50--70%                      \-                  74.53 ± 9.27
  LYM                 20--40%                      \-                  18.95 ± 7.87
  MONO                3--8%                        \-                  5.55 ± 2.48
  PLT                 (100--300) × 10^9^/L         \-                  165.33 ± 29.48
  FIB                 2.0--4.0 g/L                 \-                  3.17 ± 1.31
  APTT                31--43 s                     \-                  34.16 ± 3.95
  PT                  11--13 s                     \-                  13.20 ± 1.00
  INR                 0.94--1.29                   \-                  1.01 ± 0.10
  CREA                53--115 μmol/L               64.75 ± 10.39       80.14 ± 18.89\*\*
  BUN                 2.8--7.6 mmol/L              5.46 ± 1.54         4.18 ± 1.45\*
  UA                  208.3--428.4 μmol/L          377.06 ± 116.07     196.13 ± 74.24\*\*\*
  TP                  66--83 g/L                   73.69 ± 3.21        67.27 ± 6.55\*\*\*
  ALB                 35--52 g/L                   44.17 ± 3.19        36.22 ± 5.00\*\*\*
  GLB                 20--30 g/L                   29.52 ± 2.77        31.06 ± 3.98
  A/G                 1.10--2.50                   1.51 ± 0.22         1.22 ± 0.27\*\*\*
  AST                 \<50 U/L                     24.54 ± 7.42        30.02 ± 14.58
  ALT                 \<50 U/L                     17.56 ± 13.11       31.48 ± 13.17\*\*
  ALP                 30--120 U/L                  72.97 ± 22.97       78.51 ± 34.78
  GGT                 8--57 U/L                    21.66 ± 14.19       45.17 ± 24.31\*\*\*
  TBIL                5--21 μmol/L                 12.39 ± 5.68        13.20 ± 6.05
  DBIL                \<3.4 μmol/L                 2.51 ± 1.35         2.97 ± 1.51
  IBIL                2.0--17.0 μmol/L             9.88 ± 4.36         10.23 ± 4.70
  TG                  0.4--1.7 mmol/L              2.46 ± 1.32         1.42 ± 0.83
  TC                  3--5.7 mmol/L                4.28 ± 0.81         4.04 ± 1.40
  LDL-C               1.89--4.21 mmol/L            2.33 ± 0.66         1.98 ± 0.58
  HDL-C               1.03--1.55 mmol/L            0.80 ± 0.22         1.09 ± 0.41
                                                                       

∗

TBI-third group vs control group,

P

\< 0.05,

∗∗

TBI-third group vs control group,

P

\< 0.01,

∗∗∗

TBI-third group vs control group,

P

\< 0.001.

Protein Microarray Analysis
---------------------------

To detect the DEPs, three samples in TBI-third group and three samples in the control group (these six patients' basic information is shown in [Supplementary Data Sheet S1](#SM1){ref-type="supplementary-material"}) were performed the protein microarray analysis. Firstly, the serum samples were diluted with PH = 8.0 1 × PBS five times, and were dialyzed. Then the protein concentration of the serum samples was measured according to the operating instructions of the KC^TM^ BCA protein quantification kit (KangChen Bio-tech, Shanghai, China). Next, the samples and 1× labeling reagent were added into new tubes, mixed, and incubated for 30 min at room temperature. After that, stop solution was used for stopping the label reaction and the biotin labeled samples were dialyzed three times with dialysis tubes. Meanwhile, the RayBio^®^ Biotin label-based human antibody array 1 and 2 (including 1,000 antibodies: cytokines, chemokines, adipokines, growth factors, proteases, soluble antibodies, adhesion factors and other proteins, which all are shown in [Supplementary Data Sheet S2](#SM2){ref-type="supplementary-material"}) were balanced for 1 h at room temperature and placed at the vacuum dryer for 1 h. Then 400 ul 1× blocking buffer was added into each chip well to incubate on a shaker for 1 h at room temperature. After discarding the blocking buffer, 400 μl of the sample was added to each well and incubated overnight at 4°C with shaking. When the sample was removed, 1× wash buffer I and II were used for washing the arrays 5 min/time for three times, respectively. After that, 400 ul 1× Cy3 equivalent (diluted by 1× blocking buffer) was added into each well and incubated for 2 h at room temperature with shaking and protection from light. Similarly, the arrays were washed with 1× wash buffer I and II. Finally, the InnoScan 300 Microarray Scanner (Parc d'Activités Activestre; Carbonne-France) with wave length 532 nm and resolution 10 μm was used for detecting the fluorescent signal on the arrays. The RayBio^®^ Analysis Tool software and data analysis software of AAH-BLG-1000 were used to extract and analyze the data. The obtained fluorescence intensity data first subtracted the background and was normalized to the Positive Control signals. Differentially expressed proteins (DEPs) were obtained by comparison of the signal values between groups based on *P* \< 0.05 by *t*-test, FDR \< 0.05, and fold change (FC) \> 2 or \<0.5. In TBI-third group, the proteins more than twice the relative expression of that in the control group were defined as up-regulated proteins, and the proteins that were less than 0.5 times the relative expression of that in the control group were defined as down-regulated proteins.

Gene Ontology and KEGG Pathway Analysis of DEPs
-----------------------------------------------

In this study, we applied Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway to analyze the DEPs by using String online tools^[1](#fn01){ref-type="fn"}^. GO analysis was employed to annotate genes and gene products including molecular function, biological process, and cellular component. KEGG is a knowledge base for systematic analysis of gene functions, comprising a series of genome and enzymatic approaches and genomic information with higher order functional information ([@B16]). Accordingly, it was used for systematic analysis of gene function and related high-level genome functional information of DEPs.

Integration of Protein--Protein Interaction (PPI) Network Analysis
------------------------------------------------------------------

STRING version 10.0 covers 9,643,763 proteins obtained from 2,031 organisms ([@B38]). The STRING database (see footnote 1) is utilized to assess and predict the PPIs comprising direct (physical) and indirect (functional) associations. In order to assess the interactional relationships and build a PPI network among the DEPs, STRING tool was employed and established a PPI network according to the function and pathway enrichment analysis. *P* \< 0.05 was considered statistically significant.

Automatic Blood Biochemical Examination
---------------------------------------

The Beckman Coulter Chemistry Analyzer (AU480) (Beckman Coulter K.K., Tokyo, Japan) was used to detect the serum level of the indicators that reflect the liver and kidney function and lipid status. The Lis 2.2 software (Shanghai Medical InfoTech Co., Ltd., China) was operated for result display. Reagent detection, ion calibration, and quality control must be performed every time the sample is tested. Therefore, these three steps were performed first. Firstly, the standard reagents (Beckman Coulter Laboratory Systems Co., Ltd., Suzhou, China) were placed in the corresponding positions and the sample cups (Kangjie Medical Devices Co., Ltd., Jiangsu, China) filled with W1 cleaning solution and W2 cleaning solution (Beckman Coulter, Inc., Brea, CA, United States) were laid in the stat table. Then the reagent check was started. After, ISE High Serum Standard and ISE Low Serum Standard (Beckman Coulter, Inc., Brea, CA, United States) were then placed in the S-H and S-L positions on the stat table, respectively, for all ion calibrations. Subsequently, the quality control test was conducted. Quality control is the detection of the stability of the reagents. The sample cups with Control Serum 1 and Control Serum 2 (Beckman Coulter Ireland Inc., Co., Clare, Ireland) were placed on the sample rack (Beckman Coulter K.K., Tokyo, Japan) for quality control tests. After the tests were completed, the result was transmitted to the Lis 2.2 software. When all the tests were passed, blood biochemical examination of the samples could be performed. Clean sample cups with 300 μl of the serum sample were put on the sample racks in turn, and the items to be detected were selected for sample examination. The results were also displayed on the Lis 2.2 software.

Enzyme-Linked Immunosorbent Assay (ELISA)
-----------------------------------------

In order to determine the levels of human NGF, NT-3, HGF, IGF-2, NPY, CRP, ICAM-2, and MMP-9 in the patients' serum, the enzyme-linked immunosorbent assay (ELISA) kits were purchased from MEIMIAN (Kete Biological Technology Co., Ltd., Jiangsu, China) and used according to the manufacturer's instructions. Firstly, the microtiter plates were coated with purified NGF, NT-3, HGF, IGF-2, NPY, CRP, ICAM-2, and MMP-9 antibodies, respectively. Then blank wells, the standard wells and sample wells were set. In the sample wells, 25 μl of the sample diluent and 25 μl of a sample to be tested were added to the bottom of the wells (the final dilution of the sample is two times). At the same time, 50 ul of the standards of known concentration were added into the standards wells. Nothing was added to the blank well. After that, 100 μl HRP-conjugated reagent was added to each well except the blank well, and the plates were covered with adhesive films, mixed gently and incubated for 60 min at 37°C in the incubator (Thermo, Marietta, OH, United States). Next, the plates were rinsed five times with 1× washing solution and patted dry. Then 50 μl of substrate A and 50 μl of substrate B were added to each well and gently mixed. After incubating in the dark at 37°C for 15 min, the reaction was stopped by 50 μl of stop solution (blue at this time turned yellow). Within 15 min, the absorbance (optical density value) of each well was measured with a spectrophotometer (Thermo Fisher Scientific, Vantaa, Finland) at a wavelength of 450 nm. Finally, the linear regression equations of the standard curves were calculated using the concentration and the OD value of the standards and then the concentration of NGF, NT-3, HGF, IGF-2, NPY, CRP, ICAM-2, and MMP-9 in the serum was calculated.

Statistical Analysis
--------------------

The measurement data were statistically analyzed with an independent sample *t*-test using SPSS 16.0 software (IBM Corporation, Armonk, NY, United States). *P* \< 0.05 was considered as statistical significance. The concentrations of NGF, NT-3, HGF, IGF-2, NPY, CRP, ICAM-2, and MMP-9 in the serum were shown by mean ± standard error (SEM) and 95% confidence interval (CI). In addition to the concentrations of these molecules, other measurement data were represented as mean ± standard deviation (SD). The enumeration data was also analyzed by SPSS 16.0, and represented with the percentage.

Results
=======

Baseline Data of the Patients
-----------------------------

Baseline characteristics of all patients are shown in [Table 2](#T2){ref-type="table"}. The patients in the control group do not suffer from cerebral injury or another organic disease. In addition to traumatic brain damage, the patients of TBI-third group also aren't afflicted with other diseases. The percentage of male and female who were embedded in the control group was 53% and 47%, respectively, but 85% and 15% in TBI-third group, respectively. The ratio of male and female included in the two groups was not consistent. However, the mean age of patients in the control group and TBI-third group were 44.4 ± 20.56 and 46.4 ± 16.24 years old, respectively, with no statistical difference (*P* = 0.733). Besides, the difference in creatinine (CREA), urea nitrogen (BUN), and uric acid (UA) between the two groups was statistically significant (*P* \< 0.05), but they were all within the normal reference range. Therefore, the kidney function was not considered to be impaired in both groups. At the same time, the total protein (TP), albumin (ALB), globulin (GLB), albumin/globulin ratio (A/G), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltranspeptidase (GGT), total bilirubin (TBIL), direct bilirubin (DBIL) and indirect bilirubin (IBIL), which all reflected the liver function, in the serum of control group and TBI-third group were also completely within the normal reference range, indicating good liver function in both groups. Moreover, the triglyceride, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), which reflected the state of blood lipid, did not differ between the two groups (*P* \> 0.05). In addition to HDL-C that was less than the lower limit of the normal reference range in control group, TG, TC and LDL-C in control group, and TG, TC, LDL-C, and HDL-C in TBI-third group were all within the normal reference range, suggesting that the blood lipid level in both groups were almost normal. Furthermore, the Glasgow Coma Scale (GCS) scores of patients in control group and TBI-third groups were 15 ± 0 points and 13.25 ± 0.39 points, respectively, and the difference was statistically significant (*P* = 0.000). Additionally, CT examination revealed that the TBI patients had lesions in the forehead (70%), partes temporalis (45%), facies parietalis (35%), and occiput (15%). Hematoma occurred in 85% of the patients' lesions, which appeared in intracerebral (45%), epidural (30%), and subdural (10%). For the treatment of hematoma, 70% of patients were treated conservatively, and only 30% of patients were treated by surgery to relieve hematoma compression. Blood examination and coagulative function evaluation showed that platelet (PLT), fibrinogen (FIB), activated partial thrombin time (APTT), prothrombin time (PT), and international normalized ratio (INR) of TBI patients were within the normal reference range, illustrating that the TBI patients had normal coagulation function and no possibility of spontaneous bleeding, that meant the hematomas were caused by trauma. Simultaneously, blood examination showed that the hemoglobin (HGB) in TBI patients was 126.73 ± 16.21 g/L, demonstrating that there was no massive hemorrhage after TBI. What's more, the white blood cells (WBCs) were (9.06 ± 4.48) × 10^9^/L, and the proportions of neutrophil granulocyte (NEUT), lymphocyte (LYM), and monocyte (MONO) were (74.53 ± 9.27)%, (18.95 ± 7.87)%, and (5.55 ± 2.48)%, respectively. It can be seen that WBC and NEUT were elevated, while LYM and MONO were within normal reference range, revealing that there existed acute inflammatory response in TBI-third patients.

Heat Map Analysis of DEPs
-------------------------

The expression levels of all significantly DEPs were shown in the heat map, which comprised 107 downregulated proteins and 65 upregulated proteins ([Figure 1A-a,b,B-a,b](#F1){ref-type="fig"} and [Supplementary Data Sheet S3](#SM3){ref-type="supplementary-material"}). Moreover, the top 10 of downregulated proteins are Follistatin-like 1, beta-NGF, Lefty-A, MMP-20, EG-VEGF/PK1, Decorin, Pref-1, HAI-2, MCP-4/CCL13 and IL-22 ([Figure 1A-c](#F1){ref-type="fig"} and [Supplementary Data Sheet S3](#SM3){ref-type="supplementary-material"}), and the top 10 of upregulated proteins are I-309, SAA, Notch-1, S100 A8/A9, D-Dimer, IL-31, NT-4, CRP, MMP-9 and SCG3 ([Figure 1B-c](#F1){ref-type="fig"} and [Supplementary Data Sheet S3](#SM3){ref-type="supplementary-material"}).

![The expression profile of all the differentially expressed proteins (DEPs) in TBI-third group and control group. Here the protein expression was detected by protein microarray. In the heatmap, each column represents a sample, and each row represents a single protein. **(A-a,A-b)** Represent the down-regulated proteins, and the **(B-a,B-b)** represent the up-regulated proteins. **(A-c,B-c)** Show the top 10 of the lowest fold change proteins and the top 10 of the highest fold change proteins, respectively. The color scale shows the relative expression level of proteins in certain slide: The colors from green (left) to red (right) indicate the low to high relative expression levels, in which the green at the far left is the lowest relative expression level and the red at the far right is the highest relative expression level.](fnins-12-01049-g001){#F1}

GO Function Analysis of Differential Expressed Proteins
-------------------------------------------------------

The GO is a set of dynamic controlled vocabulary and used to describe the role of gene and protein with three major categories of information including biological process, cellular component, and molecular function. Biological process mainly involves a biological objective to which the gene or gene product contributes, and this process may be accomplished by one or more ordered assemblies of molecular functions. In this study, the DEPs were analyzed in relevant biological processes by gene annotations. The results indicated that the biological processes of downregulated proteins were involved in 212 categories, and the top 10 of biological processes were shown in Table [3A](#T3A){ref-type="table"} and [Supplementary Data Sheet S4](#SM4){ref-type="supplementary-material"}. Moreover, the biological processes of upregulated proteins were mainly 115 categories, and the top 10 biological processes were screened and shown in Table [3A](#T3A){ref-type="table"} and [Supplementary Data Sheet S5](#SM5){ref-type="supplementary-material"}. Among the three categories of GO, cellular component is related to the activation of a gene product. In this study, we found that the most expression of downregulated proteins and upregulated proteins both happened in the extracellular region, extracellular region part and extracellular space (Table [3B](#T3B){ref-type="table"} and [Supplementary Data Sheets S4](#SM4){ref-type="supplementary-material"}, [S5](#SM5){ref-type="supplementary-material"}). Molecular function is characterized by the biochemical activity of a gene product consisting of specific binding to ligands or structures. The molecular functions of downregulated proteins were mainly involved in receptor binding, protein binding, cytokine activity, growth factor activity, chemoattractant activity, cytokine receptor binding, C-C chemokine receptor activity cytokine binding, morphogen activity, and BMP binding (Table [3C](#T3C){ref-type="table"} and [Supplementary Data Sheet S4](#SM4){ref-type="supplementary-material"}), while the molecular function of upregulated proteins were consisting of protein binding, receptor binding, endopeptidase activity, growth factor activity, lipoprotein particle binding, and interleukin-6 receptor binding (Table [3C](#T3C){ref-type="table"} and [Supplementary Data Sheet S5](#SM5){ref-type="supplementary-material"}).

###### 

The top 10 biological process based on protein count of differentially expressed proteins (DEPs).

  DEPs                 Item description                                    Protein count and matching proteins
  -------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Downregulated DEPs   Single-organism cellular process                    38: ADAM11, APLN, CCL15, CCL7, CCR1, CCR2, CDH5, CER1, CHGA, CTNNB1, DLK1, EDA, ERBB3, ESRRA, FASLG, FGF8, FSTL1, HGF, ICAM2, IFNB1, IL17B, IL17C, IL24, IL26, LIF, LZTS1, MFGE8, MMP20, MPL, NBL1, NGF, NPY, NRG2, NRTN, NTF3, PGF, RTTN, VWF
                       Single organism signaling                           33: ADAM11, APLN, CCL15, CCL7, CCR1, CCR2, CDH5, CER1, CSK, CTNNB1, DLK1, EDA, ERBB3, ESRRA, FASLG, FSTL1, HGF, HTRA2, ICAM2, IFNB1, IL17B, IL17C, IL26, LIF, MPL, NGF, NPY, NRG2, NRTN, NTF3, PGF, SPARC, TF
                       Cell communication                                  33: ADAM11, APLN, CCL15, CCL7, CCR1, CCR2, CDH5, CER1, CSK, CTNNB1, DLK1, EDA, ERBB3, ESRRA, FASLG, FSTL1, HGF, HTRA2, ICAM2, IFNB1, IL17B, IL17C, IL26, LIF, MPL, NGF, NPY, NRG2, NRTN, NTF3, PGF, SPARC, TF
                       Response to stimulus                                32: ADAM11, APLN, CCL15, CCR1, CCR2, CDH5, CER1, CHGA, CTNNB1, DCN, DLK1, ERBB3, ESRRA, FASLG, HGF, ICAM2, IFNB1, IL17C, IL17D, IL17F, IL26, ITLN1, LIF, MFGE8, MPL, NGF, NPY, NRG2, NRTN, NTF3, TFPI, VWF
                       Multicellular organismal development                31: ANGPTL2, APLN, CCBP2, CCK, CDH5, CER1, CSK, CSRP2, CTNNB1, EDA, ERBB3, ERBB4, ESRRA, FASLG, FGF8, HTRA2, IFNB1, IL17F, LZTS1, MFGE8, MFRP, MMP20, NBL1, NPY, NRG2, PGF, RTTN, SPARC, SPINT2, TF, TIMP2
                       Signal transduction                                 31: ADAM11, APLN, CCL15, CCL7, CCR1, CCR2, CDH5, CER1, CSK, CTNNB1, DLK1, EDA, ERBB3, ESRRA, FASLG, FSTL1, HGF, HTRA2, ICAM2, IFNB1, IL17C, LIF, MPL, NGF, NPY, NRG2, NRTN, NTF3, PGF, SPARC, TF
                       Cellular response to stimulus                       31: ADAM11, APLN, CCL15, CCR1, CCR2, CDH5, CER1, CHGA, CTNNB1, DLK1, EDA, ERBB3, ESRRA, FASLG, FSTL1, HGF, HTRA2, ICAM2, IFNB1, IL17C, IL24, LIF, MPL, NGF, NPY, NRG2, NRTN, NTF3, SPARC, TF, TIMP2
                       Single-multicellular organism process               30: ANGPTL2, CCBP2, CCR2, CDH5, CER1, CHGA, CSRP2, CTNNB1, EDA, ERBB3, ERBB4, ESRRA, FASLG, FGF8, HTRA2, IFNB1, IL17F, LZTS1, MFGE8, MFRP, MPL, NBL1, NPY, NRG2, PGF, RTTN, SPINT2, TFPI, TIMP2, VWF
                       Regulation of metabolic process                     30: APLN, CCK, CCR1, CCR2, CER1, CSK, CTNNB1, DCN, DLK1, EDA, ERBB3, ERBB4, ESRRA, FASLG, FGF8, FSTL1, HGF, HPX, HTRA2, IFNB1, IL24, IL26, ITLN1, LIF, LZTS1, NGF, NTF3, SPINT2, TF, TFPI
                       Positive regulation of biological process           29: APLN, CCK, CCL7, CCR1, CCR2, CHGA, CTNNB1, DCN, ERBB3, ERBB4, ESRRA, FASLG, HGF, HPX, HTRA2, ICAM2, IFNB1, IL17B, IL17F, IL26, ITLN1, LIF, MFGE8, NBL1, NPY, NTF3, SPARC, TF, TIMP2
  Upregulated DEPs     Positive regulation of biological process           26: ADAM17, APOE, CCR7, CDH13, CNTF, CRP, CTSB, DLL1, EPO, FST, HCRT, IGF2, IL34, ITGA2B, KITLG, KLK14, LGMN, MFNG, MMP9, PGLYRP1, RARRES2, SAA1, SMAD4, SMAD5, TFRC, VIPR2
                       Multicellular organismal process                    24: ADAM17, APOE, CCR7, CDH13, CHRDL2, CNTF, CTSB, DAND5, DLL1, FGF18, FST, GAL, KITLG, KLK14, LGMN, MFNG, NTNG2, OLR1, PAPPA, PGA5, RARRES2, SAA1, SCG3, TFRC
                       Regulation of macromolecule metabolic process       23: ADAM17, APOE, CCR7, CDH13, CNTF, CRP, DLL1, EPO, FGF18, FST, GAL, GCG, HCRT, IGF2, IL34, KITLG, MMP9, NF1, RARRES2, SAA1, SERPINA9, SMAD4, SMAD5
                       Signal transduction                                 22: ADAM17, APOE, CCL1, CCR7, CDH13, CNTF, CTSB, DLL1, EPO, FGF18, FST, GAL, GCG, HCRT, IGF2, ITGA2B, LGMN, MMP9, PGLYRP1, SIGLEC9, SMAD4, SMAD5
                       Positive regulation of cellular metabolic process   21: ADAM17, APOE, CCR7, CDH13, CNTF, CRP, DLL1, EPO, FGF18, GAL, GCG, IGF2, IL34, KITLG, MMP9, NF1, RARRES2, SAA1, SMAD4, SMAD5, VIPR2
                       Negative regulation of cellular process             21: ADAM17, APOE, CCR7, CDH13, CHRDL2, CNTF, CRP, CTSB, DAND5, EPO, FST, HCRT, KITLG, KLK14, LGMN, MMP9, NTF4, PGLYRP1, SERPINA9, SMAD4, VIPR2
                       Negative regulation of biological process           21: ADAM17, APOE, CCR7, CDH13, CHRDL2, CNTF, CRP, CTSB, DAND5, EPO, FST, HCRT, KITLG, KLK14, MMP9, NTF4, PGLYRP1, SAA1, SERPINA9, SMAD4, VIPR2
                       Positive regulation of cellular process             21: ADAM17, APOE, CCR7, CDH13, CNTF, CRP, DLL1, EPO, HCRT, IGF2, IL34, ITGA2B, KITLG, KLK14, MFNG, MMP9, RARRES2, SAA1, SMAD4, SMAD5, VIPR2
                       Regulation of signaling                             20: ADAM17, APOE, CCR7, CDH13, CHRDL2, CNTF, DAND5, DLL1, EPO, FST, GAL, HCRT, IGF2, KITLG, KLK14, LGMN, MFNG, MMP9, SAA1, SMAD4
                       Regulation of cell communication                    20: ADAM17, APOE, CCR7, CDH13, CHRDL2, CNTF, DAND5, DLL1, EPO, FST, GAL, HCRT, IGF2, KITLG, KLK14, LGMN, MFNG, MMP9, SAA1, SMAD4
                                                                           

###### 

Cellular component of differentially expressed proteins (DEPs).

  DEPs                 Item description                             Protein count and matching proteins
  -------------------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Downregulated DEPs   Extracellular region                         40: ANGPTL2, APLN, CCL15, CCL7, CER1, CHGA, CSK, CTNNB1, DCN, DLK1, EDA, ERBB3, ERBB4, ESRRA, FASLG, FGF8, FSTL1, HPX, ICAM2, IFNB1, IL17B, IL17C, IL17D, IL17F, IL24, IL26, ITLN1, LIF, MFGE8, MMP20, NBL1, NGF, NPY, NRG2, NRTN, NTF3, SPINT2, TF, TFPI, VWF
                       Extracellular region part                    37: ANGPTL2, APLN, CCK, CCL15, CCL7, CER1, CSK, CTNNB1, DCN, DLK1, ERBB3, ESRRA, FASLG, FGF8, FSTL1, HGF, HPX, ICAM2, IFNB1, IL17B, IL17C, IL17D, IL17F, IL24, IL26, ITLN1, LIF, MFGE8, MMP20, NBL1, NPY, NRG2, PGF, SPARC, TF, TFPI, VWF
                       Extracellular space                          32: ANGPTL2, APLN, CCK, CCL15, CCL7, CER1, DCN, DLK1, ERBB3, FASLG, FGF8, FSTL1, HGF, HPX, IFNB1, IL17B, IL17C, IL17D, IL17F, IL24, IL26, LIF, MFGE8, MMP20, NBL1, NPY, NRG2, PGF, SPARC, TF, TFPI, TIMP2
                       Plasma membrane part                         18: CCBP2, CCR1, CCR2, CSK, CTNNB1, DLK1, EDA, ERBB3, ERBB4, FGF8, HTRA2, ICAM2, ITLN1, LZTS1, MFGE8, MFRP, MPL, TF
                       Cell surface                                 10: CCR1, DLK1, FASLG, FGF8, MFGE8, MPL, SPARC, TF, TFPI, TIMP2
                       Side of membrane                             7: CCR1, CSK, DLK1, FASLG, FGF8, HTRA2, MFGE8
                       Cytoplasmic membrane-bounded vesicle lumen   6: FASLG, HGF, HPX, SPARC, TF, VWF
                       Secretory granule lumen                      4: HGF, SPARC, TF, VWF
  Upregulated DEPs     Extracellular region                         37: APOE, CCL1, CDH13, CHRDL2, CNTF, CRP, CTSB, DAND5, DLL1, EPO, FGF18, FGL1, FST, GAL, GAST, GCG, HCRT, IL31, IL34, ITGA2B, KLK14, LCN2, LGMN, MFNG, MMP9, NTF4, OLR1, PAPPA, PGA5, PGLYRP1, RARRES2, SAA1, SCARB2, SCG3, SERPINA9, SLC2A5, TFRC
                       Extracellular region part                    30: APOE, CCL1, CDH13, CHRDL2, CNTF, CRP, CTSB, EPO, FGF18, FGL1, GAL, GCG, IL31, IL34, ITGA2B, KITLG, KLK14, LCN2, LGMN, MFNG, MMP9, OLR1, PGA5, PGLYRP1, RARRES2, SAA1, SCARB2, SERPINA9, SLC2A5, TFRC
                       Extracellular space                          24: APOE, CCL1, CDH13, CHRDL2, CNTF, CRP, CTSB, EPO, FGF18, FGL1, GAL, GCG, IGF2, IL31, IL34, ITGA2B, KITLG, KLK14, LCN2, MFNG, MMP9, SAA1, SERPINA9, TFRC
                       Vesicle                                      23: APOE, CDH13, CRP, CTSB, DLL1, FGL1, GAL, GCG, IGF2, ITGA2B, KLK14, LCN2, LGMN, MMP9, OLR1, PGA5, PGLYRP1, RARRES2, SAA1, SCARB2, SCG3, SLC2A5, TFRC
                       Membrane-bounded vesicle                     22: APOE, CDH13, CRP, CTSB, FGL1, GAL, GCG, IGF2, ITGA2B, KLK14, LCN2, LGMN, MMP9, OLR1, PGA5, PGLYRP1, RARRES2, SAA1, SCARB2, SCG3, SLC2A5, TFRC
                       Extracellular exosome                        19: APOE, CDH13, CRP, CTSB, FGL1, IGF2, ITGA2B, KLK14, LCN2, LGMN, MMP9, OLR1, PGA5, PGLYRP1, RARRES2, SAA1, SCARB2, SLC2A5, TFRC
                       Cytoplasmic vesicle                          10: APOE, CTSB, DLL1, GAL, GCG, IGF2, ITGA2B, SAA1, SCG3, TFRC
                       Secretory granule                            6: GAL, GCG, HCRT, IGF2, ITGA2B, SCG3
                       Side of membrane                             6: CCR7, CDH13, CTSB, ITGA2B, NF1, TFRC
                       Cytoplasmic membrane-bounded vesicle lumen   5: APOE, GCG, IGF2, SAA1, SCG3
                       External side of plasma membrane             5: CCR7, CDH13, CTSB, ITGA2B, TFRC
                                                                    

###### 

Molecular function of differentially expressed proteins (DEPs).

  DEPs                 Item description                  Protein count and matching proteins
  -------------------- --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Downregulated DEPs   Protein binding                   39: ADAM11, ANGPTL2, APLN, CCK, CCL15, CCL7, CCR1, CCR2, CDH5, CER1, CSK, CTNNB1, EDA, ERBB3, ERBB4, ESRRA, FASLG, FGF8, HGF, HTRA2, ICAM2, IFNB1, IL17B, IL17C, IL17F, IL24, IL26, LIF, NBL1, NGF, NPY, NRG2, NRTN, NTF3, PGF, SPARC, TF, TIMP2, VWF
                       Receptor binding                  31: ADAM11, ANGPTL2, APLN, CCK, CCL15, CCL7, CCR2, CDH5, CSK, CTNNB1, EDA, ERBB4, FASLG, FGF8, HGF, ICAM2, IFNB1, IL17B, IL17C, IL17F, IL24, IL26, LIF, NGF, NPY, NRG2, NRTN, NTF3, PGF, TF, VWF
                       Cytokine activity                 9: CCL15, CCL7, IFNB1, IL17B, IL17C, IL17F, IL24, IL26, LIF
                       Cytokine receptor binding         7: CCL15, CCL7, CCR2, IFNB1, LIF, NGF, NTF3
                       Growth factor activity            6: FGF8, HGF, LIF, NGF, NTF3, PGF
                       Chemoattractant activity          4: CCL15, FGF8, HGF, NTF3
                       Cytokine binding                  4: CCR1, CER1, IL17F, NBL1
                       C-C chemokine receptor activity   3: CCBP2, CCR1, CCR2
                       Morphogen activity                2: CER1, NBL1
                       BMP binding                       2: CER1, NBL1
  Upregulated DEPs     Protein binding                   27: ADAM17, APOE, CCL1, CCR7, CDH13, CNTF, CRP, CTSB, DLL1, FGF18, FST, GAL, GAST, GCG, HSPB6, IGF2, IL34, ITGA2B, KITLG, MMP9, NTF4, RARRES2, SAA1, SCARB2, SMAD4, SMAD5, TFRC
                       Receptor binding                  16: ADAM17, APOE, CCL1, CNTF, CRP, DLL1, FGF18, GAL, GAST, GCG, IGF2, IL34, KITLG, NTF4, RARRES2, SAA1
                       Endopeptidase activity            7: ADAM17, CTSB, KLK14, LGMN, MMP9, PAPPA, PGA5
                       Growth factor activity            4: CNTF, FGF18, IGF2, NTF4
                       Lipoprotein particle binding      3: APOE, CDH13, CRP
                       Interleukin-6 receptor binding    2: ADAM17, CNTF
                                                         

PPI Network Analysis of the DEPs
--------------------------------

The PPI network with obvious interaction relationship for all DEPs included 109 nodes and 293 edges, in which the network of downregulated proteins included 58 nodes and 82 edges, and the PPI network of upregulated proteins composed of 51 nodes and 74 edges ([Figure 2](#F2){ref-type="fig"}). Additionally, the top five pairs of all DEPs with the greatest combined score were TF-TFRC (0.999), CCK-GAST (0.993), NRG2-ERBB3 (0.991), GCG-GAST (0.99), and CTNNB1-CDH5 (0.988) ([Figure 2](#F2){ref-type="fig"} and [Supplementary Data Sheet S6](#SM6){ref-type="supplementary-material"}). Moreover, the top 10 proteins with the max number of interactors in the PPI network of all DEPs were MMP9 (30), HGF (25), CRP (19), NGF (18), NPY (17), VWF (17), IGF-2 (15), KITLG (15), TF (15), and EPO (13, the same as GCG and SAA1) ([Figure 2](#F2){ref-type="fig"} and [Supplementary Data Sheet S6](#SM6){ref-type="supplementary-material"}). Meanwhile, the top five pairs with the greatest combined score were NRG2-ERBB3 (0.991), CTNNB1-CDH5 (0.988), NRG2-ERBB4 (0.984), CCL7-CCR2 (0.978), CCL7-CCR1 (0.959) in the downregulated proteins, and GCG-GAST (0.99), EPO-KITLG (0.982), SMAD5-SMAD4 (0.968), GCG-VIPR2 (0.951), IGF2-PAPPA (0.948) in upregulated proteins ([Figure 2](#F2){ref-type="fig"} and [Supplementary Data Sheet S6](#SM6){ref-type="supplementary-material"}). Then the top five proteins with the max number of interactors were HGF (15), NGF (10), VWF (8), CTNNB1 (7), NPY (7) in the PPI network of downregulated proteins, and CRP (12), MMP9 (11), APOE (8), GCG (8), SAA1 (8) in the PPI network of upregulated proteins ([Figure 2](#F2){ref-type="fig"} and [Supplementary Data Sheet S6](#SM6){ref-type="supplementary-material"}). In summary, NGF (18), NT-3 (7), IGF-2 (15), HGF (18), NPY (17), CRP (19), MMP-9 (30) and ICAM-2 (2) hold the high number of interactors (shown in the brackets) and might be the core protein in PPI Network of all DEPs. Therefore, they were considered to be meaningful proteins and were for further study. Here values in brackets are the combined score value or the number of interactors.

![Intermolecular interactions of differentially expressed proteins (DEPs). The intermolecular interactions of all DEPs are shown in this figure. The lines reflect interaction relationship of DEPs. Network edges: line color indicates the type of interaction evidence from the interaction sources, line thickness indicates the strength of data support, and line shape indicates the predicted mode of action. The interaction sources: text mining, experiments, databases, co-expression, neighborhood, gene fusion, and co-occurrence. The minimum required interaction score was medium confidence 0.400. The max number of interactors to show: none or query proteins only in first shell and none in second shell. The network display mode: interactive svg (a scalable vector graphic). The set organism: homo sapiens. Colored nodes: query proteins and first shell of interactors, white nodes: second shell of interactors, empty nodes: proteins of unknown 3D structure, filled nodes: proteins with known or predicted 3D structure.](fnins-12-01049-g002){#F2}

Kyoto Encyclopedia of Genes and Genomes (KEGG) Analyses for Differentially Expressed Proteins (DEPs)
----------------------------------------------------------------------------------------------------

To analyze the enriched pathways of DEPs, KEGG analysis was performed. The results showed that the significant enriched pathways of the downregulated DEPs were cytokine--cytokine receptor interaction, PI3K-Akt signaling pathway, proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, and Jak-STAT signaling pathway ([Table 4](#T4){ref-type="table"}). Meanwhile, the enriched pathways of the upregulated DEPs were showed as follows: pathways in cancer, cytokine--cytokine receptor interaction, hematopoietic cell lineage and Notch signaling pathway ([Table 4](#T4){ref-type="table"}). Among these pathways, they were either relevant to growth or inflammation.

###### 

KEGG pathways classification of differentially expressed proteins.

  DEPs                 Pathway description                       Protein count   Matching proteins
  -------------------- ----------------------------------------- --------------- ------------------------------------------------------------------
  Upregulated DEPs     Cytokine--cytokine receptor interaction   11              CCL7, CCR1, CCR2, EDA, FASLG, HGF, IFNB1, IL17B, IL24, IL26, MPL
                       PI3K-Akt signaling pathway                7               FASLG, FGF8, HGF, IFNB1, NGF, PGF, VWF
                       Proteoglycans in cancer                   6               CTNNB1, DCN, ERBB4, FASLG, FGF8, HGF
                       Rap1 signaling pathway                    5               CTNNB1, FGF8, HGF, NGF, PGF
                       Ras signaling pathway                     5               FASLG, FGF8, HGF, NGF, PGF
                       Jak-STAT signaling pathway                4               IFNB1, IL24, IL26, MPL
  Downregulated DEPs   Pathways in cancer                        6               FGF16, FGF18, ITGA2B, KITLG, MMP9, SMAD4
                       Cytokine--cytokine receptor interaction   5               CCL1, CCR7, CNTF, EPO, KITLG
                       Hematopoietic cell lineage                4               EPO, ITGA2B, KITLG, TFRC
                       Notch signaling pathway                   3               ADAM17, DLL1, MFNG
                                                                                 

Changes of Expression of Some Growth Factors and Inflammation-Related Factors After TBI Injury
----------------------------------------------------------------------------------------------

Because of the high number of interactors of NGF, NT-3, IGF-2, HGF, NPY, CRP, MMP-9, and ICAM-2 in PPI Network, we think they may play a pivotal role in traumatic brain injury. In our study, therefore, their expression in serum was verified by ELISA. 39 sera from 19 patients in control group and 20 patients in TBI-third group were detected. Compared with control group, CRP, ICAM-2, and MMP-9 from innate immune system were significantly increased in TBI-third group, and the *P*-values were 0.008, 0.045, 0.03, respectively ([Figure 3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}). In addition, HGF, IGF-2, NGF, and NT-3 with growth factor activity were also up-regulated in TBI-third group in comparison with control group, and the difference was statistically significant, and the *P*-value were 0.038, 0.042, 0.006, 0.009, respectively ([Figure 3D](#F3){ref-type="fig"}--[G](#F3){ref-type="fig"}). Furthermore, NPY with neuropeptide hormone activity was significantly more in TBI-third group than that in control group (*P* = 0.009) ([Figure 3H](#F3){ref-type="fig"}). Moreover, the mean ± SEM value and the 95% CI of the concentration of the eight proteins in the serum of both groups were shown [Table 5](#T5){ref-type="table"}.

![Changes of expression of some growth factors and inflammation-related factors in the serum. **(A--H)** Separately showed the serum concentration of CRP, ICAM-2, MMP-9, HGF, IGF-2, NGF, NT-3, and NPY in control group and TBI-third group. The data was represent as mean ± SEM. *^∗^*TBI vs. Control, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001.](fnins-12-01049-g003){#F3}

###### 

The mean ± SEM and 95% confidence interval (CI) of the concentration of NGF, NT-3, IGF-2, HGF, CRP, ICAM-2, MMP-9, and NPY in the serum.

  Proteins   Group       Mean ± SEM                  95% CI
  ---------- ----------- --------------------------- ------------------------
  NGF        Control     (23.80 ± 16.32) *ng/ml*     (0˜58.09) ng/ml
             TBI-third   (242.16 ± 96.96) *ng/ml*    (39.21˜445.10) ng/ml
  NT-3       Control     (76.46 ± 12.10) *pg/ml*     (50.93˜101.99) pg/ml
             TBI-third   (384.84 ± 140.90) *pg/ml*   (89.92˜679.75) pg/ml
  IGF2       Control     (262.07 ± 63.68) *pg/ml*    (127.72˜396.41) pg/ml
             TBI-third   (727.37 ± 141.57) *pg/ml*   (431.06˜1023.67) pg/ml
  HGF        Control     (229.40 ± 59.76) *pg/ml*    (103.86˜354.95) pg/ml
             TBI-third   (965.60 ± 251.10) *pg/ml*   (441.81˜1489.39) pg/ml
  CRP        Control     (2.77 ± 0.89) *mg/L*        (0.90˜4.64) mg/L
             TBI-third   (7.65 ± 1.51) *mg/L*        (4.49˜10.81) mg/L
  ICAM2      Control     (3.09 ± 3.04) *ng/ml*       (0˜9.05) ng/ml
             TBI-third   (32.05 ± 13.22) *ng/ml*     (4.37˜59.72) ng/ml
  MMP9       Control     (4.79 ± 1.00) *ng/ml*       (2.68˜6.90) ng/ml
             TBI-third   (21.98 ± 7.28) *ng/ml*      (6.74˜37.21) ng/ml
  NPY        Control     (40.84 ± 8.71) *ng/ml*      (22.53˜59.15) ng/ml
             TBI-third   (107.36 ± 21.88) *ng/ml*    (61.55˜153.16) ng/ml
                                                     

Discussion
==========

In this study, the serum samples of TBI patients and healthy volunteers were subjected to protein microarray analysis and it was found that there were significant changes in many proteins, especially growth factors and inflammatory factors in the serum after TBI injury compared with control group. As everyone knows, clinical data is often influenced by many factors. In order to ensure the scientificalness of the study, the mean age and age distribution of patients in TBI-third group were the same as those in the control group. Moreover, the major indicators such as liver function, renal function and blood lipids in both groups were within normal reference range, which indicated that the liver and renal function of all cases are normal. Furthermore, all volunteers in the control group must have no other organic-related diseases, and all patients in the TBI-third group have mild-moderate damage with 11--15 points of GCS but without other organic diseases except for TBI injury. Therefore, the baseline data of both groups were almost consistent.

At the same time, in this study, the degree of traumatic brain injury was determined by CT performance and GCS score. Because of the rapid acquisition of CT images and independent changes in the patient's consciousness, routine CT examinations are known as the "gold standard" for the diagnosis of acute brain injury ([@B40]). However, CT showed poor brain parenchymal lesions, and it only had a good effect on diagnosing large-area hemorrhagic changes, large-area brain contusion and other relatively wide-ranging lesions. There is a big limitation on the diagnosis of microbleeds in brain tissue, so that the severity of traumatic brain injury was often missed or judged too lightly ([@B5]). Moreover, in the acute phase of TBI, the patients may be in a coma or critically ill and then unable to complete the large-scale tests. Therefore, CT performance combined with the clinical behavioral observations to assess the degree of damage is more reliable. The most common clinical behavioral observation is the GCS score, which scored according to coma severity ([@B3]). In this study, CT showed that the injured sites of the patients with TBI were in forehead, partes temporalis, facies parietalis and occiput, and 85% of the patients had the intracerebral, epidural or subdural hematoma. In addition, the GCS scores of these patients were 11--15 points, that is, mild and moderate coma. Therefore, the serum samples from TBI patients used for in this study also were credible.

Through bioinformatics analysis, we found the biological process of DEPs, the most of which happened in the extracellular region, extracellular region part and extracellular space, was involved in positive/negative regulation of cellular process, signaling and signal transduction, cell communication, response to stimulus, immune system process, multicellular organismal development, metabolic process, and biological process. Moreover, the molecular functions of them were involved in receptor binding, protein binding, cytokine activity, growth factor activity, chemoattractant activity, cytokine receptor binding, C-C chemokine receptor activity, cytokine binding, morphogen activity, BMP binding, and interleukin-6 receptor binding. Additionally, the most significant pathways were enriched in cytokine--cytokine receptor interaction and PI3K-Akt signaling pathway among downregulated proteins, and pathways in cancer and cytokine--cytokine receptor interaction among upregulated proteins. To sum up, these DEPs were much enriched in the biological processes and pathways related with growth and inflammation. As noted above, the secondary injury of traumatic brain injury involves a series of cellular processes ([@B46]; [@B28]), which are the result of the involvement of these DEPs. By binding with other molecules (e.g., protein, receptor, and cytokine) and the activity of growth factors and inflammatory factors, they are involved in positively or negatively regulating cellular process, signal transduction, cell communication, response to stimulus, immune system process and multicellular organismal development, etc. Then, in turn, they further promote the damage repair, or suppress or even worsen damage.

The role of growth factors and inflammatory factors in the body is mutual resistance. Growth factors can promote the recovery of neurologic damage. In contrast, inflammatory factors destroy the repair. If the growth factors and anti-inflammatory factors predominate, the prognosis of TBI patients is better; however, if the injury factors such as inflammation prevail, the prognosis will be worse. After TBI, both physical and chemical factors activate the innate immune system to cause a cascade of inflammatory reactions at the site of the injury. Inflammatory factors accumulate around the injury and diffuse into the cerebrospinal fluid and the blood, which is inextricably linked to the patient's neurological outcome. In our study, WBC and NEUT in TBI-third group were increased and more than the upper limit of normal reference range, which demonstrated that acute inflammatory reaction existed. What's more, inflammation-related factors including CRP, ICAM-2, and MMP-9 were also elevated, suggesting that after traumatic brain injury, the innate immune system was activated, then the inflammatory factors damaged the blood--brain barrier and were released into the blood. Previous studies also reported similar results. After TBI, neurological function of rats was impaired, while immediately administrating with propofol for 2 h after TBI could effectively improve neurological function ([@B20]). Simultaneously, the expressions of IL-1β, IL-6, and TNF-α within 1 week after operation were significantly augmented in the injured cortex, but markedly decreased after propofol treatment ([@B20]). In addition, after TBI injury, some interventions, such as administrated with breviscapine via the right lateral ventricle or co-transplanting NSCs with olfactory ensheathing cells (OECs) into the area surrounding the injury site, could reduce interleukin-6 expression, and significantly improved neurobehavioral dysfunction in the short-term ([@B21]; [@B15]).

On the other hand, however, it has also been reported that growth factors were involved in nerve repair. In traumatic brain injury, neurological function improvement was associated with the upregulated BDNF expression, while the blockade of BDNF exacerbated neurological function deficits ([@B44]). Similarly, after spinal cord injury (SCI), the level of BDNF also gradually increased with partial functional restoration, and BDNF overexpressing facilitated the recovery of locomotor function, while BDNF knockdown wound led to opposite outcome ([@B12]; [@B8]). Moreover, GDNF and CNTF played an essential role in neuroplasticity after TBI and the SCI, which could downregulate the expression of BAX and BAD signaling to suppress apoptosis, therefore, to improve neurological function and survival ([@B31]; [@B32]; [@B10]). Furthermore, the upregulation of NGF and NT-3 in neurons also could enhance neurons' survival and neurite outgrowth, as well as promoted motor and sensory function recovery in hind limbs after SCI ([@B47]; [@B43]; [@B45]). At present, we investigated the factors associated with growth and nerve repair by ELISA, including NGF, NT-3, HGF, IGF-2, NPY in serum, and they were found to be elevated in TBI-third group compared to the control group, which pointed out that the protective factors were playing a neuroprotective role after TBI injury.

Therefore, after TBI injury, it is a trend to inhibit its damage factors, especially the progression of inflammatory factors, and promote its protective factors, especially the growth factors and neuropeptides, which will contribute to clinical diagnosis and targeted therapies of TBI in translational medicine and clinical practice.

Conclusion
==========

In this study, we reported the protein expressional profiles in serum from TBI patients, in which the network among inflammatory factors and growth factors may play a crucial role in TBI damage and repair, which, consequently, may contribute to diagnosis and treatment in future translational medicine and clinical practice.
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BAD

:   Bcl-2 associated death promoter

BAX

:   Bcl-2 associated X protein

BDNF

:   brain-derived neurotrophic factor

BMPs

:   bone morphogenetic proteins

CNTF

:   ciliary neurotrophic factor

CRP

:   C-reactive protein

CT

:   computed tomography

GDNF

:   glial cell-derived neurotrophic factor

HGF

:   hepatocyte growth factor

HRP

:   horse radish peroxidase

ICAM2

:   intercellular adhesion molecule 2

IGF2

:   insulin like growth factor 2

MMP9

:   matrix metallopeptidase 9

NGF

:   nerve growth factor

NPY

:   neuropeptide Y

NT-3

:   neurotrophin 3

TGF-β

:   transforming growth factor β
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